← Browse by Condition
Medical Condition

castration resistant prostate carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for castration resistant prostate carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — castration resistant prostate carcinoma Clinical Trials

How many clinical trials are currently recruiting for castration resistant prostate carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for castration resistant prostate carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for castration resistant prostate carcinoma?
castration resistant prostate carcinoma research spans Phase 1 (3 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a castration resistant prostate carcinoma clinical trial?
Eligibility criteria for castration resistant prostate carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
1
Top Sponsors
Vadim S Koshkin 1 trial
City of Hope Medical Center 1 trial
Rahul Aggarwal 1 trial

Recruiting Clinical Trials

NCT05113537 Phase 1, Phase 2
Recruiting
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Enrollment
30 pts
Location
United States
Sponsor
Vadim S Koshkin
View Trial →
NCT05805371 Phase 1
Recruiting
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Enrollment
21 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT06942104 Phase 1
Recruiting
Imaging of Solid Tumors Using 18F-TRX
Enrollment
56 pts
Location
United States
Sponsor
Rahul Aggarwal
View Trial →

Related Conditions

stage ivb prostate cancer ajcc v8 (3) metastatic prostate adenocarcinoma (1) stage iv prostate cancer ajcc v8 (1) stage iva prostate cancer ajcc v8 (1) metastatic castration resistant prostate carcinoma (1) metastatic castration resistant prostate cancer (1) metastatic prostate carcinoma (1) solid tumor (1) solid carcinoma (1) locally advanced clear cell renal cell carcinoma (1) metastatic clear cell renal cell carcinoma (1) metastatic malignant solid neoplasm (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology